Cargando…
Effect of immunotherapy on overall survival in limited-stage small cell lung carcinoma: a national cancer database analysis
BACKGROUND: While immune-based therapies have been approved for extensive-stage small cell lung cancer, there is limited data on the efficacy of immunotherapy in patients with limited-stage disease. METHODS: We used the National Cancer Database to first evaluate factors associated with the inclusion...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905481/ https://www.ncbi.nlm.nih.gov/pubmed/33747146 http://dx.doi.org/10.1177/1758835920982806 |
_version_ | 1783655120059236352 |
---|---|
author | Bilani, Nadeem Alley, Evan Elson, Leah Nahleh, Zeina Arteta-Bulos, Rafael |
author_facet | Bilani, Nadeem Alley, Evan Elson, Leah Nahleh, Zeina Arteta-Bulos, Rafael |
author_sort | Bilani, Nadeem |
collection | PubMed |
description | BACKGROUND: While immune-based therapies have been approved for extensive-stage small cell lung cancer, there is limited data on the efficacy of immunotherapy in patients with limited-stage disease. METHODS: We used the National Cancer Database to first evaluate factors associated with the inclusion of immunotherapy as part of the initial therapeutic course in patients diagnosed with limited-stage small cell lung cancer (LS-SCLC). Consequently, we evaluated the impact of this immunotherapy on 2-year and 5-year overall survival (OS). We did this by performing 1:1 matching for controls that did not receive immunotherapy, and comparing survival between cohorts using the Kaplan–Meier method. RESULTS: A total of 98 patients with LS-SCLC received immunotherapy as part of their initial therapeutic regimen. Age and facility type were the only significant predictors of the use of immunotherapy. There was no statistically significant difference between matched case-control cohorts in median OS (p = 0.985), 2-year OS (p = 0.747), and 5-year OS (p = 0.934). CONCLUSION: In this study using a large national database, we found that the inclusion of immunotherapy as part of the initial systemic therapy regimen was not significantly associated with improved OS in a cohort of LS-SCLC patients. |
format | Online Article Text |
id | pubmed-7905481 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-79054812021-03-18 Effect of immunotherapy on overall survival in limited-stage small cell lung carcinoma: a national cancer database analysis Bilani, Nadeem Alley, Evan Elson, Leah Nahleh, Zeina Arteta-Bulos, Rafael Ther Adv Med Oncol Immunotherapy for Lung Cancer: Progress, Opportunities and Challenges BACKGROUND: While immune-based therapies have been approved for extensive-stage small cell lung cancer, there is limited data on the efficacy of immunotherapy in patients with limited-stage disease. METHODS: We used the National Cancer Database to first evaluate factors associated with the inclusion of immunotherapy as part of the initial therapeutic course in patients diagnosed with limited-stage small cell lung cancer (LS-SCLC). Consequently, we evaluated the impact of this immunotherapy on 2-year and 5-year overall survival (OS). We did this by performing 1:1 matching for controls that did not receive immunotherapy, and comparing survival between cohorts using the Kaplan–Meier method. RESULTS: A total of 98 patients with LS-SCLC received immunotherapy as part of their initial therapeutic regimen. Age and facility type were the only significant predictors of the use of immunotherapy. There was no statistically significant difference between matched case-control cohorts in median OS (p = 0.985), 2-year OS (p = 0.747), and 5-year OS (p = 0.934). CONCLUSION: In this study using a large national database, we found that the inclusion of immunotherapy as part of the initial systemic therapy regimen was not significantly associated with improved OS in a cohort of LS-SCLC patients. SAGE Publications 2021-02-23 /pmc/articles/PMC7905481/ /pubmed/33747146 http://dx.doi.org/10.1177/1758835920982806 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Immunotherapy for Lung Cancer: Progress, Opportunities and Challenges Bilani, Nadeem Alley, Evan Elson, Leah Nahleh, Zeina Arteta-Bulos, Rafael Effect of immunotherapy on overall survival in limited-stage small cell lung carcinoma: a national cancer database analysis |
title | Effect of immunotherapy on overall survival in limited-stage small
cell lung carcinoma: a national cancer database analysis |
title_full | Effect of immunotherapy on overall survival in limited-stage small
cell lung carcinoma: a national cancer database analysis |
title_fullStr | Effect of immunotherapy on overall survival in limited-stage small
cell lung carcinoma: a national cancer database analysis |
title_full_unstemmed | Effect of immunotherapy on overall survival in limited-stage small
cell lung carcinoma: a national cancer database analysis |
title_short | Effect of immunotherapy on overall survival in limited-stage small
cell lung carcinoma: a national cancer database analysis |
title_sort | effect of immunotherapy on overall survival in limited-stage small
cell lung carcinoma: a national cancer database analysis |
topic | Immunotherapy for Lung Cancer: Progress, Opportunities and Challenges |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905481/ https://www.ncbi.nlm.nih.gov/pubmed/33747146 http://dx.doi.org/10.1177/1758835920982806 |
work_keys_str_mv | AT bilaninadeem effectofimmunotherapyonoverallsurvivalinlimitedstagesmallcelllungcarcinomaanationalcancerdatabaseanalysis AT alleyevan effectofimmunotherapyonoverallsurvivalinlimitedstagesmallcelllungcarcinomaanationalcancerdatabaseanalysis AT elsonleah effectofimmunotherapyonoverallsurvivalinlimitedstagesmallcelllungcarcinomaanationalcancerdatabaseanalysis AT nahlehzeina effectofimmunotherapyonoverallsurvivalinlimitedstagesmallcelllungcarcinomaanationalcancerdatabaseanalysis AT artetabulosrafael effectofimmunotherapyonoverallsurvivalinlimitedstagesmallcelllungcarcinomaanationalcancerdatabaseanalysis |